Lost in translation? A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies

References

• Wolmarans De W, Brand L, Stein DJ, et al. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density. Behav Brain Res. 2013;256:545–553.
   PubMed Web of Science ®Google Scholar
• Tucci MC, Dvorkin-Gheva A, Johnson E, et al. 5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD). Behav Brain Res. 2015;279:211–217.
   PubMed Web of Science ®Google Scholar
• Joel D. The signal attenuation rat model of obsessive-compulsive disorder: a review. Psychopharmacology. 2006;186(4):487–503.
   PubMed Web of Science ®Google Scholar
• Njung’e K, Handley SL. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol. 1991;104(1):105–112.
   PubMed Web of Science ®Google Scholar
• Hoffman KL. Animal models of obsessive compulsive disorder: recent findings and future directions. Expert Opin Drug Discov. 2011;6(7):725–737.
   PubMed Web of Science ®Google Scholar
• Hoffman KL. Modeling neuropsychiatric disorders in laboratory animals. Cambridge: Woodhead Publishing; 2015.
   Google Scholar
• Camilla d’Angelo LS, Eagle DM, Grant JE, et al. Animal models of obsessive-compulsive spectrum disorders. CNS Spectr. 2014;19(1):28–49.
   PubMed Web of Science ®Google Scholar
• Greenberg BD, Price LH, Rauch SL, et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am. 2003;14(2):199–212.
   PubMed Web of Science ®Google Scholar
• Baxter LR. Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. J Clin Psychiatry. 1990;51(Suppl:22–5):discussion 26.
   Google Scholar
• Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res. 1990;85:119–146.
   PubMed Web of Science ®Google Scholar
• Haber SN. Corticostriatal circuitry. Dialogues Clin Neurosci. 2016;18(1):7–21.
   PubMed Web of Science ®Google Scholar
• Baxter LR Jr., Saxena S, Brody AL, et al. Brain mediation of obsessive-compulsive disorder symptoms: evidence from functional brain imaging studies in the human and nonhuman primate. Semin Clin Neuropsychiatry. 1996;1(1):32–47.
   PubMedGoogle Scholar
• O’Regan JB. Treatment of obsessive–compulsive neurosis with haloperidol. Can Med Assoc J. 1970;103(2):167–168.
   PubMed Web of Science ®Google Scholar
• Capstick N. Chlorimipramine in obsessional states. (A pilot study). Psychosomatics. 1971;12(5):332–335.
   PubMed Web of Science ®Google Scholar
• Collins GH. Hypertension during chlorimipramine therapy. Br Med J. 1971;2(5754):170–171.
   PubMedGoogle Scholar
• Pitman RK. Animal models of compulsive behavior. Biol Psychiatry. 1989;26(2):189–198.
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Ryland DH, Kriete M. Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(7):517–521.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Shoulberg N, Helton K, et al. The neuroethological approach to obsessive-compulsive disorder. Compr Psychiatry. 1992;33(4):274–281.
   PubMed Web of Science ®Google Scholar
• Yadin E, Friedman E, Bridger WH. Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav. 1991;40(2):311–315.
   PubMed Web of Science ®Google Scholar
• Woods A, Smith C, Szewczak M, et al. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl). 1993;112(2–3):195–198.
   PubMed Web of Science ®Google Scholar
• Altemus M, Glowa JR, Murphy DL. Attenuation of food-restriction-induced running by chronic fluoxetine treatment. Psychopharmacol Bull. 1993;29(3):397–400.
   PubMedGoogle Scholar
• Einat H, Szechtman H. Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole. Physiol Behav. 1995;57(1):55–59.
   PubMed Web of Science ®Google Scholar
• Andersen SL, Greene-Colozzi EA, Sonntag KC. A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals. Biol Psychiatry. 2010;68(8):741–747.
   PubMed Web of Science ®Google Scholar
• Hoffman KL, Hornig M, Yaddanapudi K, et al. A murine model for neuropsychiatric disorders associated with group A beta-hemolytic streptococcal infection. J Neurosci. 2004;24(7):1780–1791.
   PubMed Web of Science ®Google Scholar
• Garner JP, Mason GJ. Evidence for a relationship between cage stereotypies and behavioural disinhibition in laboratory rodents. Behav Brain Res. 2002;136:83–92.
   PubMed Web of Science ®Google Scholar
• Greene-Schloesser DM, Van Der Zee EA, Sheppard DK, et al. Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav Brain Res. 2011;221:55–62.
   PubMed Web of Science ®Google Scholar
• Cano-Ramírez H, Hoffman KL. Activation of the orbitofrontal and anterior cingulate cortices during the expression of a naturalistic compulsive-like behavior in the rabbit. Behav Brain Res. 2017;320:67–74.
   PubMed Web of Science ®Google Scholar
• Garner JPMeehan CL, Mench Ja. Stereotypies In Caged Parrots, Schizophrenia And Autism: Evidence For A Common Mechanism. Behav Brain Res. 2003;145:125–134
   Google Scholar
• Seibert LM, Crowell-Davis SL, Wilson GH, et al. Placebo-controlled clomipramine trial for the treatment of feather picking disorder in cockatoos. J Am Anim Hosp Assoc. 2004;40:261–269.
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Keshavan MS. A.E. Toward a neurodevelopmental model of obsessive–compulsive disorder. Biol Psychiatry. 1998;43(9):623–640.
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096–1103.
   PubMed Web of Science ®Google Scholar
• Campbell KM, De Lecea L, Severynse DM, et al. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci. 1999;19(12):5044–5053.
   PubMed Web of Science ®Google Scholar
• Presti MF, Watson CJ, Kennedy RT, et al. Behavior-related alterations of striatal neurochemistry in a mouse model of stereotyped movement disorder. Pharmacol Biochem Behav. 2004;77(3):501–507.
   PubMed Web of Science ®Google Scholar
• Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007;448(7156):894–900.
   PubMed Web of Science ®Google Scholar
• Ade KK, Wan Y, Hamann HC, et al. Increased metabotropic glutamate receptor 5 signaling underlies obsessive-compulsive disorder-like behavioral and striatal circuit abnormalities in mice. Biol Psychiatry. 2016;80(7):522–533.
   PubMed Web of Science ®Google Scholar
• Servaes S, Glorie D, Verhaeghe J, et al. Preclinical molecular imaging of glutamatergic and dopaminergic neuroreceptor kinetics in obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:90–98.
   PubMed Web of Science ®Google Scholar
• Aida T, Yoshida J, Nomura M, et al. Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice. Neuropsychopharmacology. 2015;40(7):1569–1579.
   PubMed Web of Science ®Google Scholar
• Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716–721.
   PubMed Web of Science ®Google Scholar
• Grant PJ, Joseph LA, Farmer CA, et al. 12 week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology. 2014;39:1453–1459.
   PubMed Web of Science ®Google Scholar
• Pittenger C, Bloch MH, Wasylink S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot placebo-controlled trial. J Clin Psychiatry. 2015;76(8):1075–1084.
   PubMed Web of Science ®Google Scholar
• Emamzadehfard S, Kamaloo A, Paydary K, et al. Riluzole in augmentation of fluvoxatine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016;70:332–341.
   PubMed Web of Science ®Google Scholar
• Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2011;26:221–224.
   PubMed Web of Science ®Google Scholar
• Nicola M, Tedeschi D, Martinotti G, et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. A 16 week case series. J Clin Psychopharmacol. 2011;31(5):675–677.
   PubMed Web of Science ®Google Scholar
• Egashira N, Okuno R, Harada S, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol. 2008;586(1–3):164–170.
   PubMed Web of Science ®Google Scholar
• Andreasen JT, Fitzpatrick CM, Larsen M, et al. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action. Brain Res. 2015;1601:117–126.
   PubMed Web of Science ®Google Scholar
• Egashira N, Okuno R, Abe M, et al. Calcium-channel antagonists inhibit marble-burying behavior in mice. J Pharmacol Sci. 2008;108(1):140–143.
   PubMed Web of Science ®Google Scholar
• Arora T, Bhowmik M, Khanam R, et al. Oxcarbazepine and fluoxetine protect against mouse models of obsessive compulsive disorder through modulation of cortical serotonin and CREB pathway. Behav Brain Res. 2013;247:146–152.
   PubMed Web of Science ®Google Scholar
• Walker DL, Ressler KJ, Lu KT, et al. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22(6):2343–2351.
   PubMed Web of Science ®Google Scholar
• Storch EA, Wilhelm S, Sprich S, et al. Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(8):779–788.
   PubMed Web of Science ®Google Scholar
• Andersson E, Hedman E, Enander J, et al. d-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):659–667.
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2009;43(6):664–670.
   PubMed Web of Science ®Google Scholar
• Wu PL, Tang HS, Lane HY, et al. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol. 2011;31(3):369–374.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry. 2005;162(11):2191–2192.
   PubMed Web of Science ®Google Scholar
• Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004;174(4):530–538.
   PubMed Web of Science ®Google Scholar
• Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl). 2013;228(4):633–640.
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47:175–180.
   PubMed Web of Science ®Google Scholar
• Stryjer R, Budnik D, Ebert T, et al. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Clin Neuropharmacol. 2014;37(3):79–81.
   PubMed Web of Science ®Google Scholar
• Albelda N, Bar-On N, Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2010;210(1):13–24.
   PubMed Web of Science ®Google Scholar
• Iijima M, Kurosu S, Chaki S. Effects of agents targeting glutamatergic systems on marble-burying behavior. Neurosci Lett. 2010;471(2):63–65.
   PubMed Web of Science ®Google Scholar
• Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294–321.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Mohammadi MR, Bahraini S, et al. A. Efficacy of N-Acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial. Iran J Psychiatry. 2017;12(2):134–141.
   PubMedGoogle Scholar
• Paydary K, Akamaloo A, Ahmadipour A, et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214–219.
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797–803.
   PubMed Web of Science ®Google Scholar
• Costa DLC, Diniz JB, Requena G, et al. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017. DOI:10.4088/JCP.16m11101
   PubMedGoogle Scholar
• Sarris J, Oliver G, Camfield DA, et al. N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29(9):801–809.
   PubMed Web of Science ®Google Scholar
• Egashira N, Shirakawa A, Abe M, et al. N-acetyl-L-cysteine inhibits marble-burying behavior in mice. J Pharmacol Sci. 2012;119(1):97–101.
   PubMed Web of Science ®Google Scholar
• Esalatmanesh S, Abrishami Z, Zeinoddini A, et al. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial. Psychiatry Clin Neurosci. 2016;70(11):517–526.
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Shahhossenie M, Mesgarpour B, et al. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: a randomized double-blind study. Hum Psychopharmacol. 2017;32:4.
   Web of Science ®Google Scholar
• Kalinichev M, Le Poul E, Bolea C, et al. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. J Pharmacol Exp Ther. 2014;350(3):495–505.
   PubMed Web of Science ®Google Scholar
• Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol. 2004;501(1–3):121–125.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18(9):557–574.
   PubMed Web of Science ®Google Scholar
• Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry. 2004;12(6):305–320.
   PubMed Web of Science ®Google Scholar
• Sesia T, Bizup B, Grace AA. Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity. Int J Neuropsychopharmacol. 2013;16(6):1295–1307.
   PubMed Web of Science ®Google Scholar
• Hatalova H, Radostova D, Pistikova A, et al. Spatial reversal learning in chronically sensitized rats and in undrugged sensitized rats with dopamine D2-like receptor agonist quinpirole. Front Behav Neurosci. 2014;8:122.
   PubMed Web of Science ®Google Scholar
• De Haas R, Seddik A, Oppelaar H, et al. Marked inbred mouse strain difference in the expression of quinpirole induced compulsive like behavior based on behavioral pattern analysis. Eur Neuropsychopharmacol. 2012;22(9):657–663.
   PubMed Web of Science ®Google Scholar
• De Carolis L, Schepisi C, Millela MS, et al. Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior. Psychopharmacology (Berl). 2011;218(4):749–759.
   PubMed Web of Science ®Google Scholar
• Eagle DM, Noschang C, d’Angelo LS, et al. The dopamine D2/D3 receptor agonist quinpirole increases checking-like behaviour in an operant observing response task with uncertain reinforcement: a novel possible model of OCD. Behav Brain Res. 2014;264:207–229.
   PubMed Web of Science ®Google Scholar
• Berridge KC, Aldridge JW, Houchard KR, et al. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette’s. BMC Biol. 2005;3:4.
   PubMed Web of Science ®Google Scholar
• Hoffman KL, Rueda Morales RI. D1 and D2 dopamine receptor antagonists decrease behavioral bout duration, without altering the bout’s repeated behavioral components, in a naturalistic model of repetitive and compulsive behavior. Behav Brain Res. 2012;230(1):1–10.
   PubMed Web of Science ®Google Scholar
• Egashira N, Okuno R, Matsushita M, et al. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. Eur J Pharmacol. 2008;592(1–3):103–108.
   PubMed Web of Science ®Google Scholar
• Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35(2):57–61.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Casarotto PC, Resstel LB, et al. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):434–438.
   PubMed Web of Science ®Google Scholar
• Kinsey SG, O’Neal ST, Long JZ, et al. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav. 2011;98(1):21–27.
   PubMed Web of Science ®Google Scholar
• Heidari M, Zarei M, Hosseini SM, et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2014;29(6):344–350.
   PubMed Web of Science ®Google Scholar
• Askari N, Moin M, Sanati M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012;26(10):883–892.
   PubMed Web of Science ®Google Scholar
• Shalbafan M, Mohammadinejad P, Shariat SV, et al. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2015;48(4–5):136–140.
   PubMed Web of Science ®Google Scholar
• Mowla A, Boostani S, Dastgheib SA. Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-bline controlled clinical trial. J Clin Psychopharmacol. 2016;36(6):720–723.
   PubMed Web of Science ®Google Scholar
• Krass M, Runkorg K, Wegener G, et al. Nitric oxide is involved in the regulation of marble-burying behavior. Neurosci Lett. 2010;480(1):55–58.
   PubMed Web of Science ®Google Scholar
• Gawali NB, Chowdhury AA, Kothavade PS, et al. Involvement of nitric oxide in anticompulsive-like effect of agmatine on marble-burying behaviour in mice. Eur J Pharmacol. 2016;770:165–171.
   PubMed Web of Science ®Google Scholar
• Matsushima Y, Shirota O, Kikura-Hanajiri R, et al. Effects of Psilocybe argentipes on marble-burying behavior in mice. Biosci Biotechnol Biochem. 2009;73(8):1866–1868.
   PubMed Web of Science ®Google Scholar
• Flaisher-Grinberg S, Klavir O, Joel D. The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2008;11(6):811–825.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Yatsugi S, Yamaguchi T. Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model. Jpn J Pharmacol. 2002;90(2):197–200.
   PubMedGoogle Scholar
• Bruins Slot LA, Bardin L, Auclair AL, et al. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol. 2008;19(2):145–152.
   PubMed Web of Science ®Google Scholar
• Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008;33(6):1323–1335.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–1740.
   PubMed Web of Science ®Google Scholar
• Insel TR. From animal models to model animals. Biol Psychiatry. 2007;62:1337–1339.
   PubMed Web of Science ®Google Scholar
• Hoffman KL. New dimensions in the use of rodent behavioral tests for novel drug discovery and development. Expert Opin Drug Discov. 2016;11(4):343–353.
   PubMed Web of Science ®Google Scholar